Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy
| Autor: | Ronald J. Moleski, Gene A. Gibson, R. Jake Jacobs, Thomas A. Paivanas, Gary Milkovich, John Reitan, Susan Wyant, David M. Dunning |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
medicine.medical_specialty Neutropenia Filgrastim medicine.medical_treatment Antineoplastic Agents Sargramostim Neoplasms Internal medicine Granulocyte Colony-Stimulating Factor medicine Humans Pharmacology (medical) Adverse effect Retrospective Studies Myelosuppressive Chemotherapy Chemotherapy Cross-Over Studies business.industry Granulocyte-Macrophage Colony-Stimulating Factor Retrospective cohort study Middle Aged Recombinant Proteins Surgery Granulocyte colony-stimulating factor Granulocyte macrophage colony-stimulating factor Female business medicine.drug |
| Zdroj: | Pharmacotherapy. 20:1432-1440 |
| ISSN: | 0277-0008 |
| Popis: | Study Objective. To compare rates of adverse events with filgrastim versus sargramostim when given prophylactically to patients receiving myelosuppressive chemotherapy. Design. Retrospective review with center crossover. Setting. Ten United States outpatient chemotherapy centers. Patients. Four hundred ninety patients treated for lung, breast, lymphatic system, or ovarian tumors. Intervention. Prophylactic use of filgrastim or sargramostim, with dosages at investigator discretion. Measurements and Main Results. The frequency and severity of adverse events and the frequency of switching to the alternative CSF were assessed. There was no difference in infectious fever. Fever unexplained by infection was more common with sargramostim (7% vs 1%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text